CA-INSPUR-INFORMATION
23.3.2022 09:11:08 CET | Business Wire | Press release
Inspur Information, a leading IT infrastructure provider, launched the new A6 server line that supports 3rd Gen AMD® EPYCTM Milan/Milan-X 7003 series processors. The A6 server line features multi-core capabilities that show outstanding performance leaps compared to previous generation of servers with an up to 28% performance increase in SPEC performance test. The A6 server line will serve as the foundation for compute-intensive applications in the enterprise scenarios, such as big data, multi-cloud and other high-demand computing applications.
“By launching the brand new A6 servers, Inspur aims to deliver better compute performance for reliable and efficient business support. The Inspur A6 server series features best-in-class performance, energy efficiency and scalability to address the enormous computing challenges imposed by the era of big data and digital transformation”, said Ricky Zhao, Deputy General Manager of Server Product Line and General Manager of Datacenter Product Line, Inspur Information.
“AMD has been collaborating with Inspur to deliver innovative and high-performance products to the market”, said Roger Benson, Senior Director of AMD. “The new A6 server line powered by AMD EPYCTM Milan/Milan-X 7003 series processors represents the latest achievement by AMD and Inspur. With multi-core configurations and a series of performance optimizations, this server solution will unleash more possibilities for handling complex and compute-intensive workloads.”
A6 servers showcase outstanding performance with multiple cores with a high-base frequency, providing industry-leading single core capabilities. Storage density and IOPS (input/output operations per second) are increased by more than threefold. With the precision engineering and multi-level security mechanisms, A6 servers are more intelligent, easy-to-use and safer. They ensure efficient and care-free operation. It is designed with open computing standards, such as the ORS6000E rack.
A6 servers are designed to provide ultimate performance
NF3180A6/ NF3280A6 is a 1U/2U 1S rack server based on 3rd Gen AMD® EPYCTM Milan processors. Powered by multiple cores with a high-base frequency, it can serve as a high-density and cost-effective rack server that delivers strong computing power comparable to traditional dual-socket servers. With the addition of flexible expansion, it can fulfill the specific requirements for cloud computing, distributed storage, big data, CDN, video transcoding, in-memory database and virtualization scenarios.
Inspur NF5180A6/NF5280A6, powered by 3rd Gen AMD® EPYCTM processors, is a high-density dual-socket server that offers strong computing performance, ecological compatibility and configuration flexibility. This server features high quality and strong reliability, which makes it the ideal choice for a variety of complicated workloads, especially data processing, virtualization, high performance and cloud computing.
Inspur i24A6 is a 2U4N multi-node server adopting AMD EPYC™ 7002/7003 processors. It has 24 storage drives, multiple network options, and 8x 3200 MHz RDIMM/LRDIMM. It is tailored for high-performance computing and hyper-scale, and other tasks that require high core counts, large storage capacity and flexible I/O solutions.
Inheriting the design DNA of Inspur Information’s renowned server products, the A6 server line represents industry-leading performance, design and security. The line will serve as an engine to promote industrial AI and digital transformation by offering a foundation for a variety of key scenarios including multi-cloud, high-performance computing and edge computing.
About Inspur Information
Inspur Information is a leading provider of data center infrastructure, cloud computing, and AI solutions. It is the world’s 2nd largest server manufacturer. Through engineering and innovation, Inspur Information delivers cutting-edge computing hardware design and extensive product offerings to address important technology sectors such as open computing, cloud data center, AI, and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle specific workloads and real-world challenges. To learn more, visit https://www.inspursystems.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005391/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom